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ABSTRACT
Purpose: Atypical glands (ASAP) are diagnosed in 5.0% of prostate biopsies, and cancer identification in a rebiopsy is 
higher than 40.0%. The use of antibodies to mark basal cells is currently a common practice, in order to avoid rebiopsies. 
There has been no reported study that has reviewed characteristics of radical prostatectomies (RPs) when immunohisto-
chemistry (IHC) was necessary for definitive diagnosis.
Materials and Methods: Out of 4127 biopsies examined from 2004 to 2008, 144 (3.5%) were diagnosed with ASAP. IHC 
was performed using antibody anti-34βE12 and p63. The results of surgical specimens of 27 patients treated by RP after 
the diagnosis of prostate cancer (PC) was made using IHC (Group 1) were compared with 1040 patients where IHC was 
not necessary (Group 2).
Results: IHC helped to diagnose PC in 103 patients (71.5%). Twenty-seven (26.2%) underwent RP. In Group 1, two (7.4%) 
adenocarcinomas were insignificant versus 29 (2.9%) for Group 2. Patients from Group 1 were younger (p = 0.039), had lower 
Gleason scores (GS) (p < 0.001), lower percentage of Gleason pattern 4 (p < 0.001), and smaller tumors (p < 0.001).
Conclusion: The use of IHC did not lead to diagnosis of insignificant tumors as illustrated by absence of differences in 
pathological stage or positive surgical margins in men submitted to RP. Therefore, our results suggest that this modality 
should be routinely used for a borderline biopsy and ASAP cases.
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INTRODUCTION
 Atypical glands suspicious for carcinoma, 
also denominated atypical small acinar proliferation 
(ASAP), is not a specific entity but represents a large 
group of lesions which includes lesions that mimic 
cancer and, most importantly, carcinomas that lack all 
the cytological and/or architectural characteristics for 
the establishment of a definitive diagnosis of cancer. 
 Clinical Urology 
doi: 10.1590/S1677-55382010000500008 
The frequency of this diagnosis is variable from 0.7 to 
23.4%, with a mean of 5.0%, as reviewed by Epstein 
and Herawi (1). The possibility of diagnosing cancer 
in a subsequent biopsy is high, mean 40.2% (1-3). 
After radical prostatectomy (RP), the majority of cases 
are determined to be low grade and organ-confined 
(2,4,5).
 In 1984, Gown and Vogel (6) reported the use 
of a monoclonal antibody anti-high molecular weight 
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cytokeratin (34βE12) to mark basal cells of the pros-
tate that was later demonstrated as a characteristic of 
benign glands that retain the basal cell layer (7-9). In 
a larger series, Wojno and Epstein (10) used 34βE12 
to diagnose adenocarcinoma in suspicious glands 
identified in needle prostate biopsies. Shah et al. (11) 
later proposed the combined use of p63, an homolog 
of  the p53 tumor suppressor protein, as an auxiliary 
for the determination of cancer since it is also a protein 
expressed selectively by the basal cells of epithelial 
organs, including the prostate gland (12,13).
 Recently, lower levels of prostate specific 
antigen (PSA) have been used to indicate the need 
for a prostate biopsy, and there has been an increasing 
number of cores taken in each biopsy session. These 
new practices have resulted in the representation of 
smaller tumors, often more adequately named ASAP. 
In addition, pathologists frequently use immunohis-
tochemistry to enhance their diagnostic capabilities 
in order to avoid rebiopsies. There have been reports 
of false-positives and false-negatives for use of the 
combined 34βE12 and p63 cocktail. To date there 
has been no reported study that reviews surgical 
specimens of tumors from patients who underwent 
RP after a diagnosis of carcinoma in which the use of 
immunohistochemistry was necessary for the defini-
tive diagnosis.
MATERIALS AND METHODS
 From January 1st 2004 to July 31st 2008, 4127 
biopsies were examined in our laboratory. ASAP was 
the diagnosis made for 144 (3.5%) of the biopsies. The 
mean age of the patients was 60.8 years old, median 
60 ranging from 40 to 84 years old. Mean PSA was 
7.11 ng/mL, with a median of 5.3 ng/mL, ranging 
from 1.4 to 43.5 ng/mL. The free to total relation of 
PSA was mean 15.1%, median 13.0%, ranging from 
1 to 30%. The major reason for a biopsy among these 
patients was a progressive increase in PSA levels. One 
patient had a familiar history, and two had shown ab-
normalities in transrectal examination. In 31 patients 
(21.5%), ultrasound examination found abnormalities, 
hypoecoic and hypervascular areas. Twenty patients 
(13.9%) had previously undergone biopsies. The mean 
number of cores taken per biopsy session was 15.8, 
median 14, ranging from 6 to 40. All the slides were 
examined by the same uropathologist.
 The immunohistochemistry was performed 
using a mouse monoclonal antibody anti-high mo-
lecular weight cytokeratin (clone 34βE12, Dako, 
Glostrup, Denmark) at a dilution of 1/100 and p63 
(clone 4A4, Dako, Glostrup, Denmark) at a dilution 
of 1/100. After paraffin removal and hydration, the 
slides were immersed in 10 mM citrate buffer pH 
6, for 15 min for antigen retrieval. The antibodies 
were incubated overnight at 4°C, and the secondary 
biotin-labeled antibody was incubated for 30 min at 
room temperature. The streptavidin labeled strepta-
vidin-biotin amplification method (Dako K0679) was 
carried out for 30 minutes followed by peroxidase/di-
aminobenzidine substrate/chromagen. The slides were 
counterstained with hematoxylin.
 RP was carried out in 27 out of 144 patients. 
The results were compared to 1040 patients who 
underwent RP during the same period and where the 
histology was sufficient to define adenocarcinoma. All 
patients were treated by the same group of surgeons. 
The surgical specimens were routinely examined 
in toto by the same pathologist. To measure tumor 
volume we used the grid method as described by 
Humphrey and Vollmer (14).
RESULTS
 Immunohistochemistry permitted the de-
finitive diagnosis of prostate cancer in 103 patients 
(71.5%) (Figure-1). The mean age of patients was 
61.7 years old, median 61 (range 43 - 84); mean PSA 
was 7.6 ng/mL, median 5.4 ng/mL (range 1.4 - 44 
ng/mL); and PSA free to total ratio was mean 15%, 
median 13% (range 1 - 29%). The mean Gleason 
score was 5.9, median 6 (range 4 to 7). The mean and 
median number of cores positive for tumor was 1.4 
and 1 respectively, ranging from 1 to 4. The higher 
percentage of a single core that made up the tumor 
was mean 18.3%, median 10% (range 1 to 80%). The 
mean total percentage of tumor in all cores was 1.6%, 
median 1% (range 1 to 7%). Perineural invasion was 
not detected in any cases.
 We had access to the surgical specimens from 
27 (26.2%) patients who underwent radical prostatec-
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tomy. For the same period, from January 1 2004 to 
July 31 2008, 1040 patients also underwent radical 
prostatectomy after a diagnosis of adenocarcinoma 
that did not necessitate immunohistochemistry for 
the final diagnosis. The former will be referred to as 
Group 1, and the control group as Group 2. The char-
acteristics of both groups are shown in Table-1. There 
were no pT0 in any of the two groups. Within Group 
Table 1 – Demographic description and tumor characteristics of patients submitted to radical prostatectomy for treatment 
of prostate cancer. Group 1 represents patients where immunohistochemistry was used for the definitive diagnosis. Group 
2 represents patients where the diagnosis was made without any complementary study.
Group 1
(27)
Group 2
(1040) p Value
Age years old
Median (Q1 - Q3)
56
(53 - 65)
61
(55 - 67) 0.039
Gleason Score
Median (Q1 - Q3)
6
(6 - 6)
7
(6 - 7) < 0.001
% of pattern 4 of Gleason
Median (Q1 - Q3)
0
(0 - 17.75)
50
(9 – 100) <0.001
Tumor volume %
Median  (Q1 - Q3)
3
(2.5 - 8.0)
11
(6 - 18) <0.001
Stage
pT2
pT3
25 (92.6%)
2 (7.4%)
824 (79.2%)
216 (20.8%)
0.089
Positive surgical margins 6 (22.2%) 253 (24.3%) 0.801
Figure 1 – Immunohistochemistry study of prostate biopsy with atypical small acinar proliferation, where a diagnosis of adenocarci-
noma was made because of the absence of basal cells in the neoplastic glands. A normal gland is represented at the top of the figure 
with basal cells stained by antibodies anti-high molecular weight cytokeratin 34βE12 (A) and anti-p63 (B).
A B
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1, two (7.4%) adenocarcinomas could be considered 
clinically insignificant, defined as less than 2% of the 
gland involved, organ-confined and with no Gleason 
4 or 5 pattern present, versus 29 (2.9%) insignificant 
cases in Group 2 (15).
 The patients in Group 1 were younger, had 
lower Gleason scores, a lower percentage of Gleason 
pattern 4 and smaller tumors. However, the rate of 
positive surgical margins was similar and there were 
no differences in pathological stage.
COMMENTS
 The use of IHC as an auxiliary in the diagnosis 
of adenocarcinoma is a common practice in uropathol-
ogy, and the use of antibodies against p63 and high 
molecular weight cytokeratin has been recommended 
as adjuncts in confirming prostatic carcinoma in 
doubtful cases.
 Although basal cell markers, such as 
34βE12 and p63 antibodies are useful for identify-
ing basal cells, several benign mimickers of PC, 
such as atrophy, atypical adenomatous hyperplasia, 
nephrogenic adenoma, and mesonephric hyper-
plasia, can stain negatively with these markers. In 
addition, with patients being submitted to prostate 
biopsy with lower PSA levels and with larger 
numbers of cores being taken in each biopsy ses-
sion, concern that patients are being overtreated 
is common.
 Our results show that there was no overdiag-
nosis of PC with any pT0 after radical prostatectomy, 
with only 7.4% of cases classified as clinically insig-
nificant. Tumor stage was similar for both groups, 
but only 7.4% of patients from Group 1 had stage 
pT3 tumors. On the other hand, positivity of surgical 
margins, a very important parameter related to the 
outcome of patients submitted to radical prostatec-
tomy, mainly in organ-confined tumors (16,17), was 
similar for both groups; 22.2% and 24.3% in groups 
1 and 2, respectively.
 This is the first study to our knowledge to 
show histological characteristics of radical prostatec-
tomy specimens in men submitted to surgery to treat 
adenocarcinoma where was necessary to use IHC for 
final diagnosis.
CONCLUSION
 Our data show that the usage of IHC did not 
lead to diagnosis of insignificant tumors, as dem-
onstrated by the study of the radical prostatectomy 
specimens that had similar pathological stage and 
positive surgical margins rates. Therefore, our results 
show that this modality should be routinely used to 
evaluate a borderline biopsy and ASAP cases.
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EDITORIAL COMMENT
 Immunohistochemistry (IHC) for 34βE12 and 
p63 is at present a diagnostic standard for determining 
the presence of prostate cancer. It is also used to dis-
criminate cancer from mimic cancer, when the definite 
diagnosis is difficult with conventional microscopic 
examinations; however, second biopsy is frequently 
recommended in practice. Indeed, 34 - 60% patients 
showing atypical small acinar proliferation (ASAP) 
in the primary biopsies were diagnosed with prostate 
cancer in repeat biopsy sessions (1,2).
 As the authors stressed in the present paper, 
few studies have intentionally examined surgical 
specimens in patients with prostate cancer, who were 
primarily diagnosed with so-called atypical glands 
in previous biopsy specimens. Also, recent biopsy 
protocols such as multi-cores or saturation method 
has lead to an increase of ASAP (3). The authors 
elaborated patients’ demographics as well as radi-
cal prostatectomy specimens, of which preoperative 
diagnosis in biopsy cores required 34βE12 and p63 
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EDITORIAL COMMENT
 This study was carried out in order to in-
vestigate the value of immunohistochemstry (IHC) 
in borderline pathological prostate cancer cases. 
Immunostaining has gained an important role in the 
evaluation of borderline biopsy cases, especially when 
high-grade prostate intraepithelial neoplasia (HGPIN) 
and atypical small acinar proliferation (ASAP) are 
present. The predictive values of ASAP and HPGIN 
for cancer detection on repeat biopsies are 39 and 
23%, respectively (1). Usually, the presence of ASAP 
in the initial biopsy tissue requires re-biopsy within 
6-12 months considering other clinical features (age, 
comorbidities etc.). Although this topic has not been 
sufficiently discussed in the literature, it may have a 
significant impact on patient management. It has been 
previously recommended that a second biopsy should 
IHC, to underscore the characteristics and outcome 
of this type of prostate cancer.
 It is of interest that the patients in the IHC-
required group were younger, had lower Gleason 
score and lower fraction with Gleason pattern 4, and 
had smaller tumor foci, compared with those in the 
IHC-unnecessary group. These facts may be relevant 
to lead-time bias in patients examined during differ-
ent era with a different screening protocol, or simply 
based on earlier disease in younger patients. Although 
pathological T-stage and positive surgical margin 
rates were not statistically different between the two 
groups, the difference in patients’ number between 
them possibly explains this contradiction. Also, the 
IHC-required group was considered to include good-
risk cases, while the fraction of patients diagnosed 
with insignificant cancer was not large (7.4%). Posi-
tive surgical margin cases were distributed uniformly 
between the IHC-required and IHC-unnecessary 
groups, suggesting that 34βE12 and p63 IHC was 
useful as a preoperative diagnostics even for patients 
showing equivocal results in biopsy specimens with 
routine histology.
include extensive sampling of the initial atypical site 
as well as adjacent ipsilateral and contralateral sites 
with routine extended schemes. However, extensive 
transrectal sampling may increase the risk of infec-
tion (2). Herein the authors demonstrate that imuno-
histochemical approach, using monoclonal antibody 
anti-high molecular weight cytokeratin and p63, may 
assist in a more accurate diagnosis of ASAP and, 
therefore, may obviate the need for re-biopsies with 
the potential complications. The main benefit from 
this study should be related to diagnosis and pretreat-
ment judgment.
 This study shows comparable tumor stage in 
both study groups (radical prostatectomy after IHC 
diagnosis and control) and recommends the inclusion 
of IHC in ASAP cases work-up.
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EDITORIAL COMMENT
 Authors compared the pathologic stage between 
radical prostatectomy cases performed in patients for 
which cancer was diagnosed with the help of combined 
34βE12 and p63 cocktail IHC (n = 27) or not (n = 1040). 
Their results showed that there was no overdiagnosis of 
prostate cancer with any stage pT0 after radical prosta-
tectomy, with only 7.4% of cases classified as clinically 
insignificant. This shows the interest of IHC staining 
and the quality of the pathologist reading.
 Pathologists frequently use immunohisto-
chemistry to enhance their diagnostic capabilities in 
order to avoid rebiopsies in cases of diagnosis diffi-
culty, which is a frequent situation in biopsy reading. 
I would make 2 comments:
1) Recent studies recommend not to use the ASAP 
definition but atypical foci
2) It was also demonstrated that a different IHC of a 
p63/alpha-methyl-CoA-racemase (p504s) cock-
tail in case of atypical foci in the prostate has a 
diagnostic utility (1-3).
 Authors did not use this p504s in their IHC 
study. It may be discussed whether the addition of 
the p504s is superior or not to the 34βE12 and p63 
cocktail authors used.
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 This study contributes to our daily clinical 
practice and may have major impact on our judgment 
in borderline prostate biopsy cases. Similar studies 
evaluating novel methods to enhance biopsy-based 
diagnosis accuracy should be encouraged in view 
of the intriguing concept of active surveillance. This 
study also leads to a yet another question - does active 
or passive surveillance miss cases of significant tu-
mors that should be treated more aggressively? Future 
studies are warranted to answer this question.
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REPLY BY THE AUTHORS
To Dr. Arnauld Villers Comment
 ASAP is a term that has been discussed in 
uropathology meetings, and some pathologists argu-
ment that the suspicious gland is not always small, 
so it should be called atypical focus. ASAP was a 
very good term coined to describe doubtful lesions, 
and has been used for a long time. It means for us, 
pathologists, the presence of a small focus of atypi-
cal glands, not necessarily small, highly suspicious 
for cancer and help pathologists and urologists to 
communicate. Also, used as a keyword facilitates 
the search in the literature, whereas atypical has a 
profuse meaning. Concerning the use of alpha-meth-
yl-CoA-racemase (p504s), it has been shown that it 
stains number of benign prostate glands, periurethral 
glands and mimics of prostate cancer (1), increases 
the cost and help the final decision in only 50% of 
cases (2).
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